• Financing led by new investor TCGX, alongside Goldman Sachs Alternatives, Avoro Ventures, and venBio
• Funding will support and accelerate development of next-generation multivalent respiratory virus vaccines using proprietary Molecular Clamp technology
• Commenced Phase I clinical study of bivalent vaccine targeting both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV)

---

London, UK, 23 September 2024: Vicebio Ltd (“Vicebio”), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, today announces a $100 million Series B financing  led by TCGX  with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio,  and participation from UniQuest and founding investor Medicxi.

Vicebio is developing next-generation vaccines for respiratory viruses utilising its proprietary Molecular Clamp technology, discovered at The University of Queensland. This novel technology uniquely stabilises viral glycoproteins in their highly immunogenic ‘prefusion’ conformation, crucial for eliciting strong protective immune responses. This innovative approach enables the production of highly effective vaccines that are easy to manufacture and will be available in ready-to-use prefilled syringes. The Molecular Clamp technology is applicable to a wide range of viruses including Respiratory Syncytial Virus (RSV), Human Metapneumovirus (hMPV), Parainfluenza virus, Influenza and Coronaviruses, as confirmed by promising preclinical and clinical studies.

Vicebio has recently initiated a Phase I clinical trial with VXB-241, its bivalent vaccine targeting both RSV and hMPV, viruses that cause a significant burden of disease in elderly patients and those with a weakened immune system. There is currently no commercially available vaccine targeting RSV and hMPV. Initial clinical readouts of the Phase 1 study are expected mid 2025. This financing will also support the acceleration and expand further development of Vicebio’s multivalent pipeline including VXB-251, a trivalent vaccine targeting RSV, hMPV and Parainfluenza Virus 3 (PIV3), a further valency that addresses a significant remaining medical burden in the elderly. 

Dr Emmanuel Hanon, Chief Executive Officer of Vicebio, said: “The support from these high-calibre investors underscores the robust data package we have generated for VXB-241, highlighting the significant potential of our proprietary Molecular Clamp technology to develop next-generation vaccines against respiratory viruses.”

Cariad Chester, Managing Partner at TCGX, said: “At TCGX, we are dedicated to supporting the translation of cutting-edge science into transformative medicines and we are thrilled to partner with Vicebio. This is a highly experienced team with a breakthrough technology to address a critical public health need. Vicebio has a unique capability to advance vaccine products that simultaneously provide robust immune responses against multiple respiratory pathogens. We look forward to working closely with the team to bring these important vaccines to the market.”

Dr Giovanni Mariggi, Chairman of Vicebio and Partner at Medicxi, said: “Vicebio has made significant progress in developing its Molecular Clamp platform and successfully advanced VXB-241 which offers unmatched vaccine coverage against respiratory viruses. We are pleased to welcome TCGX, Goldman Sachs, Avoro Ventures and venBio to the syndicate to support the fight against life-threatening respiratory viral infections.”

In connection with the financing, the Vicebio Board of Directors will expand to include Cariad Chester, Managing Partner at TCGX, Colin Walsh, Managing Director at Goldman Sachs and Mark Chin, Partner at Avoro Ventures.

---

For further information, please contact:

Optimum Strategic Communications

Mary Clark, Hana Malik, Vareen Outhonesack

Tel: +44 (0) 203 922 0889

Email: [email protected]